Healthcare Costs Hit a Breaking Point, Squeezing American Businesses

NEW YORK, NY – July 27, 2026 – A chilling new forecast suggests the financial strain of providing employee health benefits is about to intensify dramatically. According to a landmark survey from consulting firm Segal, the cost trend for employer-sponsored medical plans is projected to hit 9.9 percent in 2027, a benchmark not seen in 15 years. This signal of distress is not an isolated finding; reports from Aon and PwC project similarly steep increases of 9.5 and 9 percent, respectively, confirming a market-wide trend that is pushing businesses toward a critical inflection point.

“We have seen elevated medical trends for several years, but costs now feel like they’re reaching a breaking point,” said Edward Kaplan, National Health Practice Leader at Segal. His sentiment captures a palpable sense of exasperation spreading through boardrooms and benefits departments across the country. Employers, already navigating wage inflation and supply chain pressures, are now confronting a multi-front battle against healthcare inflation driven by a complex mix of pharmaceutical innovation, technological disruption, flawed policy, and unchecked market consolidation.

The Anatomy of an Unprecedented Cost Surge

Unlike past periods of rising costs, the current surge is not attributable to a single factor but rather a convergence of powerful, interlocking forces. The first is a pharmacy boom, with prescription drug cost trends projected to outpace medical costs at 11.5 percent. This is fueled largely by the meteoric rise of specialty drugs, particularly GLP-1 anti-obesity medications. While these drugs represent a significant clinical breakthrough, their high price tags and expanding use are placing immense pressure on plan budgets, with traditional cost controls like generics proving insufficient to offset the new spending.

Simultaneously, the implementation of artificial intelligence in medical billing has become a double-edged sword. Segal's survey attributes approximately 20 percent of inpatient cost growth to increased coding intensity enabled by AI. Corroborating this, a March 2026 study from the Blue Cross Blue Shield Association found AI tools were leading to a sharp increase in severe diagnoses without a corresponding change in patient treatment. Researchers estimate that this practice, where AI identifies more lucrative billing codes, may be adding over $2.3 billion in system costs nationwide, effectively turning a tool for efficiency into an engine for inflation.

A third driver stems from the unintended consequences of well-meaning legislation. The No Surprises Act was designed to protect patients from surprise medical bills, creating an Independent Dispute Resolution (IDR) process to settle payment disputes between insurers and out-of-network providers. However, the mechanism has backfired. “Medical providers prevail 88 percent of the time in No Surprises Act disputes, at costs much higher than standard in-network rates,” explained Eileen Flick, Leader of Healthcare Informatics at Segal. This has generated an estimated $5 billion in excess system costs since 2022, transforming a patient protection law into a source of systemic cost growth.

Finally, years of unchecked industry consolidation have created a landscape with limited competition and immense pricing power. As private equity expands its footprint and hospital systems merge, employers and insurers are left with fewer negotiating partners. Research consistently shows that provider consolidation leads to significantly higher prices, with some hospital mergers driving price increases of over 60 percent. This market concentration creates a foundation of high prices upon which all other inflationary pressures are layered.

The Employer’s Dilemma: Navigating a Cost Crisis

The convergence of these factors leaves employers, the primary sponsors of health coverage in the U.S., in an exceedingly difficult position. “There is a growing frustration with the lack of transparency and the feeling that costs are spiraling out of control, no matter what we do,” commented one anonymous benefits director for a national retail chain. This sentiment is widespread, as businesses face the difficult choice between absorbing unsustainable cost increases or passing them on to employees.

Shifting costs to workers through higher premiums and deductibles is a common tactic, but it comes with its own risks. Such moves can make it harder to attract and retain talent in a competitive labor market and may lead employees to delay or forgo necessary care, potentially resulting in worse health outcomes and higher costs down the line. According to a recent Mercer survey, 59 percent of employers planned to make cost-cutting changes to their health plans in 2026, a significant jump from previous years, signaling that the pressure is becoming untenable.

A Pivot Toward Proactive Management

Faced with this daunting environment, plan sponsors are abandoning passive approaches and adopting more aggressive, data-driven strategies to reclaim control. “While the feeling of exasperation is palpable throughout the economy, there is benefit to taking an active role in managing plan costs,” advised Eric Miller, a Vice President and Consulting Actuary at Segal.

This active management includes a pivot toward direct, hard-dollar savings strategies. One key area is network optimization, where employers deploy narrow networks, enter into direct contracts with high-value provider systems, and steer employees toward centers of excellence known for better outcomes at lower costs. Another critical strategy is site-of-care steerage, which involves incentivizing patients to use lower-cost settings like ambulatory surgical centers or home infusion services instead of expensive hospital environments for routine procedures and treatments.

A significant battleground is emerging in the pharmacy space, with a push for transparent contracting. Many employers are moving away from traditional, opaque models with pharmacy benefit managers (PBMs) that rely on hidden rebates and spread pricing. Instead, they are demanding pass-through pricing arrangements that provide full visibility into the actual cost of drugs, allowing them to better manage their single largest area of spending growth.

The Long Shadow of Policy and Regulation

While corporate strategies can mitigate some of the damage, the scale of the problem points to systemic issues that require a policy response. The flawed implementation of the No Surprises Act has already drawn bipartisan concern in Congress, with lawmakers questioning why the process has strayed so far from its original intent to lower costs. The debate over PBM reform and the need for greater antitrust enforcement to curb healthcare consolidation is also gaining momentum in Washington.

For business leaders and investors, these policy debates are now critical growth signals to monitor. The future trajectory of healthcare costs, and the subsequent impact on corporate balance sheets and the broader economy, will be shaped not only by market forces but by the legislative and regulatory actions taken to address these structural flaws. The current crisis has made it clear that simply accepting annual cost increases is no longer a viable strategy.